Protalix BioTherapeutics, Inc. (NYSE: PLX) announced today positive interim efficacy and safety data from the Company's ongoing phase I/II clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE